Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware 19711; email:
Annu Rev Plant Biol. 2016 Apr 29;67:669-701. doi: 10.1146/annurev-arplant-043015-111812. Epub 2016 Feb 22.
Monoclonal antibodies (mAbs) have a wide range of modern applications, including research, diagnostic, therapeutic, and industrial uses. Market demand for mAbs is high and continues to grow. Although mammalian systems, which currently dominate the biomanufacturing industry, produce effective and safe recombinant mAbs, they have a limited manufacturing capacity and high costs. Bacteria, yeast, and insect cell systems are highly scalable and cost effective but vary in their ability to produce appropriate posttranslationally modified mAbs. Plants and green algae are emerging as promising production platforms because of their time and cost efficiencies, scalability, lack of mammalian pathogens, and eukaryotic posttranslational protein modification machinery. So far, plant- and algae-derived mAbs have been produced predominantly as candidate therapeutics for infectious diseases and cancer. These candidates have been extensively evaluated in animal models, and some have shown efficacy in clinical trials. Here, we review ongoing efforts to advance the production of mAbs in plants and algae.
单克隆抗体（mAbs）在现代有广泛的应用，包括研究、诊断、治疗和工业用途。对 mAbs 的市场需求很高且持续增长。尽管目前主导生物制造行业的哺乳动物系统能够生产有效且安全的重组 mAbs，但它们的生产能力有限，成本高昂。细菌、酵母和昆虫细胞系统具有高度可扩展性和成本效益，但在产生适当的翻译后修饰 mAbs 的能力上有所不同。植物和绿藻作为有前途的生产平台正在兴起，因为它们具有时间和成本效率、可扩展性、缺乏哺乳动物病原体和真核翻译后蛋白修饰机制。到目前为止，植物和藻类来源的 mAbs 主要作为治疗传染病和癌症的候选药物生产。这些候选药物已经在动物模型中进行了广泛评估，其中一些在临床试验中显示出了疗效。在这里，我们综述了在植物和藻类中生产 mAbs 的进展。
